Switching from Oral Risperidone 5 mg to Long-Acting Injectable
For a patient stable on oral risperidone 5 mg daily, initiate Risperdal Consta 37.5 mg intramuscularly every 2 weeks, continue the oral risperidone 5 mg daily for exactly 3 weeks after the first injection, then discontinue the oral medication. 1
Dosing Conversion
The FDA-approved conversion strategy is straightforward:
- Oral risperidone ≤4 mg/day → Risperdal Consta 25 mg every 2 weeks
- Oral risperidone >4 to ≤6 mg/day → Risperdal Consta 37.5 mg every 2 weeks
- Oral risperidone >6 mg/day → Risperdal Consta 50 mg every 2 weeks
Since your patient is on 5 mg daily, this falls into the middle category requiring 37.5 mg every 2 weeks 1.
Research data supports a slightly more conservative conversion (oral >3 to ≤5 mg → 37.5 mg LAI), which aligns well with the 5 mg dose 2. This study found that patients receiving lower LAI doses relative to their oral dose showed increased symptom scores and higher relapse tendency, reinforcing that 37.5 mg is appropriate for 5 mg oral.
Critical Oral Overlap Period
The 3-week oral supplementation period is non-negotiable. Risperdal Consta has a unique pharmacokinetic profile with delayed release—therapeutic plasma concentrations are not achieved until approximately 3 weeks after the first injection 1. During this lag period, continuing oral risperidone prevents symptom breakthrough and relapse.
- Give the first Risperdal Consta injection
- Continue oral risperidone 5 mg daily for exactly 21 days
- Discontinue oral medication on day 22
- Second LAI injection occurs on day 14 (while still on oral supplementation)
Administration Details
Route and technique matter for efficacy:
- Deep intramuscular injection only—never intravenous 1
- Deltoid: 1-inch needle, alternating arms
- Gluteal: 2-inch needle, alternating buttocks
- Must be administered by healthcare professional
- Avoid inadvertent injection into blood vessels 1
Dose Adjustments
If symptoms are not adequately controlled after 4 weeks on 37.5 mg:
- May increase to 50 mg every 2 weeks (maximum dose) 1
- Wait at least 4 weeks between dose adjustments—clinical effects of dose changes are not apparent for 3 weeks due to the medication's release kinetics 1
- Do not make premature dose increases; the delayed pharmacokinetics require patience
Alternative: Monthly Subcutaneous Formulation
If considering Perseris (RBP-7000) instead:
- For oral risperidone 6 mg daily, use 180 mg subcutaneous monthly (given as two 90-mg injections) 3
- For 5 mg oral, 120 mg monthly would be more appropriate based on proportional dosing
- No oral supplementation required—achieves therapeutic levels within hours 4
- Subcutaneous abdominal or upper arm administration 3
The newer risperidone ISM formulation also eliminates oral overlap, but Risperdal Consta remains the most established option with extensive safety data 4.
Common Pitfalls to Avoid
- Stopping oral medication too early—this is the most critical error and will result in relapse
- Inadequate injection technique—superficial injection or wrong needle length reduces bioavailability
- Premature dose escalation—waiting less than 4 weeks doesn't allow assessment of true response
- Forgetting the 2-week injection schedule—missing doses by even a few days can drop plasma levels below therapeutic range
Monitoring
After switching, the LAI formulation typically shows:
- Lower peak plasma concentrations (25-32% lower than oral) 5
- Reduced plasma fluctuations (32-42% less variability) 5
- Potentially lower side effects, particularly extrapyramidal symptoms and prolactin elevation 2, 6
- Stable symptom control equivalent to oral formulation 2, 5
The smoother pharmacokinetic profile often translates to better tolerability while maintaining efficacy, which supports the value of LAI formulations beyond just adherence benefits 7.